RTP Mobile Logo
Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia (Audio Program)
Released March 2020

A special audio supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Drs Daniel A Pollyea and Richard M Stone. (Audio Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

    Acute myeloid leukemia (AML) is the most common form of leukemia among adults, and even with adequate therapy, the 5-year survival rate among all risk groups is only about 20%. Despite the frequency of AML and its associated morbidity and mortality, until recently, standard treatment algorithms for this disease have largely remained unchanged. For patients who are not candidates for intensive induction chemotherapy, such as the elderly, little consensus has been established on an optimal management approach, and the intent of therapy is maximizing quality of life. In recent years, the identification of specific molecular aberrations, such as FLT3 and IDH1/2 mutations and Bcl-2 overexpression, which lend themselves to effective targeted therapeutic interventions, and the development of novel drug formulations are successfully redefining current treatment approaches for AML. However, along with these many exciting advances, multiple questions and clinical challenges remain.

    This CME program, developed from interviews recorded after a satellite symposium on AML held at the 2019 American Society of Hematology Annual Meeting, features investigator perspectives on recent advances in AML. By providing information on the latest clinical developments in the context of expert perspectives, this activity will assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn will facilitate optimal patient care.


    • Recognize how age, performance status and other biologic and disease-related factors affect the selection of therapy for patients with various presentations of AML.
    • Use available research evidence with approved and emerging FLT3 inhibitors to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring FLT3 mutations.
    • Develop an understanding of the latest data with and current clinical role of available IDH1/2 inhibitors for patients with AML with an IDH1 or IDH2 mutation.
    • Recall available evidence supporting the FDA approval of venetoclax-based combination regimens for patients with newly diagnosed AML, and identify individuals who are appropriate candidates for this strategy.
    • Implement a plan of care to prevent, recognize and/or manage side effects and toxicities associated with the use of recently approved systemic therapies in the management of AML to support quality of life and continuation of treatment.
    • Assess the mechanisms of action of and emerging data with investigational strategies demonstrating promising activity in AML, and refer appropriate patients for participation in ongoing trials evaluating these approaches.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Daniel A Pollyea, MD, MS
    Associate Professor of Medicine
    Clinical Director of Leukemia Services
    Robert H Allen, MD Chair in Hematology Research
    Division of Hematology
    University of Colorado School of Medicine
    Aurora, Colorado

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, argenx, Celgene Corporation, Celyad, Forty Seven Inc, Gilead Sciences Inc, Janssen Biotech Inc, Pfizer Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Genentech, Takeda Oncology; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: GlycoMimetics Inc, Tolero Pharmaceuticals.

    Richard M Stone, MD
    Director, Translational Research, Leukemia Division
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Amgen Inc, argenx, Arog Pharmaceuticals Inc, Astellas, BioLineRx, Celgene Corporation, Daiichi Sankyo Inc, Novartis, Pfizer Inc, Takeda Oncology, Trovagene; Data and Safety Monitoring Board/Committee: argenx, Celgene Corporation, Takeda Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc and Genentech.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

Acknowledge and close

Listen to audio:
Select publications
Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia (Audio Program)
Released March 2020

A special audio supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Drs Daniel A Pollyea and Richard M Stone. (Audio Program)